For research use only
| Cat No. | ABC-TC0888 |
| Product Type | Human Ovarian Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Spleen |
| Product Code | OV TOKO, ovtoko |
OVTOKO exhibits epithelial-mesenchymal traits and aggressive growth, making it suitable for modeling ovarian clear cell carcinoma invasion and drug.
OVTOKO is a human ovarian clear cell adenocarcinoma (OCCC) cell line established from splenic metastatic tumor of a woman who had previously undergone CAP (cyclophosphamide, doxorubicin, and cisplatin) chemotherapy. OVTOKO exhibits an epithelial-like morphology with adherent growth properties. These cells harbor an aneuploid karyotype, typically within the hypotriploid range. This cell line shows strong co-expression of cytokeratins 7/8/18/19, as well as EGFR and vimentin, reflecting both epithelial and mesenchymal traits. They are negative for tumor-associated antigens CA19-9 and CA125, which helps distinguish them from other ovarian cancer subtypes. This cell line displays aggressive tumorigenic and metastatic potential, forming peritoneal implants and distant metastases upon intraperitoneal transplantation in nude mice. These features make OVTOKO a valuable model for studying tumor progression mechanisms and therapeutic strategies.
| Product Code | OV TOKO, ovtoko |
| Species | Human |
| Cat.No | ABC-TC0888 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Spleen |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
The OVTOKO cell line serves as a valuable preclinical model for studying the pathobiology of ovarian clear cell carcinoma, particularly in the context of malignant progression and chemoresistance. Originating from a patient with prior CAP chemotherapy, OVTOKO cells provide a controlled environment to study the molecular mechanisms of drug resistance, tumor adaptation, and therapeutic response in resistant ovarian cancer. Its unique phenotypic and molecular characteristics make it an indispensable tool for identifying potential therapeutic targets aimed at overcoming resistance and improving clinical outcomes in patients with ovarian clear cell carcinoma.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
